Can a growth-oriented biotech giant outpace a value-leaning pharmaceutical titan? Choosing between Amgen Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) requires weighing current income against future pipeline potential in an evolving market. Amgen focuses on specialized biological medicines, while Pfizer operates as a global pharmaceutical powerhouse with a broad footprint in vaccines and primary care. Both companies face patent cliffs and regulatory shifts, making this comparison essential for investors looking to balance risk and dividend stability heading into 2027. In its latest annual report, filed for the fiscal year ended Dec. 31, 2025, Amgen describes its focus on oncology and rare diseases. It delivers medicines to patients in approximately 100 countries through distributors like McKesson Corp. (NYSE:MCK), Cencora Inc. (NYSE:COR), and Cardinal Health Inc. (NYSE:CAH). These three partners account for 77% of revenue, and customer concentration like this adds a layer of risk to the business.
CryptoAlerta — análise de criptomoedas e mercado em tempo real